Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms SJ000988500 |
Target |
Action degraders |
Mechanism JAK2 degraders(Tyrosine-protein kinase JAK2 degraders) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC38H40N10O5 |
InChIKeyJKVWQNULVWSWIV-UHFFFAOYSA-N |
CAS Registry2595365-45-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 10 May 2021 | |
Rheumatoid Arthritis | Preclinical | United States | 10 May 2021 |